These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26572562)

  • 1. Sample size under the additive hazards model.
    McDaniel LS; Yu M; Chappell R
    Clin Trials; 2016 Apr; 13(2):188-98. PubMed ID: 26572562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
    Jachno K; Heritier S; Wolfe R
    BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of survival distributions in clinical trials: A practical guidance.
    Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
    Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
    Royston P; B Parmar MK
    Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.
    Quartagno M; Morris TP; Gilbert DC; Langley RE; Nankivell MG; Parmar MK; White IR
    Clin Trials; 2023 Dec; 20(6):594-602. PubMed ID: 37337728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Power and sample size calculation for the additive hazard model.
    Su PF
    J Biopharm Stat; 2017; 27(4):571-583. PubMed ID: 27294342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size formula for proportional hazards modelling of competing risks.
    Latouche A; Porcher R; Chevret S
    Stat Med; 2004 Nov; 23(21):3263-74. PubMed ID: 15490425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
    Weir IR; Trinquart L
    Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size for testing difference between two proportions for the bilateral-sample design.
    Qiu SF; Tang NS; Tang ML; Pei YB
    J Biopharm Stat; 2009 Sep; 19(5):857-71. PubMed ID: 20183448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.
    Kombrink K; Munk A; Friede T
    Stat Med; 2013 Aug; 32(18):3055-66. PubMed ID: 23508697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
    Phadnis MA; Wetmore JB; Mayo MS
    Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size calculation for the proportional hazards cure model.
    Wang S; Zhang J; Lu W
    Stat Med; 2012 Dec; 31(29):3959-71. PubMed ID: 22786805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size.
    Xu R; Mehrotra DV; Shaw PA
    Pharm Stat; 2019 May; 18(3):366-376. PubMed ID: 30706642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Power and sample size calculation for log-rank test with a time lag in treatment effect.
    Zhang D; Quan H
    Stat Med; 2009 Feb; 28(5):864-79. PubMed ID: 19152230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Power and sample size for randomized phase III survival trials under the Weibull model.
    Wu J
    J Biopharm Stat; 2015; 25(1):16-28. PubMed ID: 24895942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size planning with the cost constraint for testing superiority and equivalence of two independent groups.
    Guo JH; Chen HJ; Luh WM
    Br J Math Stat Psychol; 2011 Nov; 64(3):439-61. PubMed ID: 20704777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size in cluster-randomized trials with time to event as the primary endpoint.
    Jahn-Eimermacher A; Ingel K; Schneider A
    Stat Med; 2013 Feb; 32(5):739-51. PubMed ID: 22865817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.